Whitehawk Therapeutics (WHWK) EPS (Weighted Average and Diluted) (2019 - 2026)
Whitehawk Therapeutics (WHWK) reported EPS (Weighted Average and Diluted) of -$0.32 for Q1 2026, down 117.49% year-over-year from $1.83 in Q1 2025, and up 13.51% quarter-over-quarter from -$0.37 in Q4 2025.
Whitehawk Therapeutics (WHWK) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.32 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.32, down 117.49% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.71 (down 1240.0% YoY), and the FY2025 annual result was -$0.33, up 86.02% from the prior year.
- EPS (Weighted Average and Diluted) grew to -$0.32 in Q1 2026 per WHWK's latest filing, from -$0.37 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $1.83 in Q1 2025 and troughed at -$0.87 in Q2 2022.
- A 5-year average of -$0.43 and a median of -$0.6 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2025 and 2026: EPS (Weighted Average and Diluted) jumped 369.12% in 2025, then plunged 117.49% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.48 in 2022, then slipped by 25.0% to -$0.6 in 2023, then dropped by 13.33% to -$0.68 in 2024, then soared by 45.59% to -$0.37 in 2025, then rose by 13.51% to -$0.32 in 2026.
- Business Quant data shows WHWK's EPS (Weighted Average and Diluted) at -$0.32 in Q1 2026, -$0.37 in Q4 2025, and -$0.26 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | -0.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.32 |
| Dec 31, 2025 | -0.37 |
| Sep 30, 2025 | -0.26 |
| Jun 30, 2025 | -0.76 |
| Mar 31, 2025 | 1.83 |
| Dec 31, 2024 | -0.68 |
| Sep 30, 2024 | -0.46 |
| Jun 30, 2024 | -0.54 |
| Mar 31, 2024 | -0.68 |
| Dec 31, 2023 | -0.60 |
| Sep 30, 2023 | -0.60 |
| Jun 30, 2023 | -0.67 |
| Mar 31, 2023 | -0.57 |
| Dec 31, 2022 | -0.48 |
| Sep 30, 2022 | -0.68 |
| Jun 30, 2022 | -0.87 |
| Mar 31, 2022 | -0.66 |
| Dec 31, 2021 | 6.96 |
| Sep 30, 2021 | -9.17 |
| Jun 30, 2021 | -0.60 |